Skip to main content
NCBI home page
ACS Central Science logoLink to ACS Central Science
. 2022 Oct 28;8(11):1537–1547. doi: 10.1021/acscentsci.2c00456

Peptide Carbocycles: From −SS– to −CC– via a Late-Stage “Snip-and-Stitch”

Samuel Gary 1, Steven Bloom 1,*
PMCID: PMC9686213  PMID: 36439308

Abstract

graphic file with name oc2c00456_0008.jpg

One way to improve the therapeutic potential of peptides is through cyclization. This is commonly done using a disulfide bond between two cysteine residues in the peptide. However, disulfide bonds are susceptible to reductive cleavage, and this can deactivate the peptide and endanger endogenous proteins through covalent modification. Substituting disulfide bonds with more chemically robust carbon-based linkers has proven to be an effective strategy to better develop cyclic peptides as drugs, but finding the optimal carbon replacement is synthetically laborious. We report a new late-stage platform wherein a single disulfide bond in a cyclic peptide can serve as the progenitor for any number of new carbon-rich groups, derived from organodiiodides, using a Zn:Cu couple and a hydrosilane. We show that this platform can furnish entirely new carbocyclic scaffolds with enhanced permeability and structural integrity and that the stereochemistry of the new cycles can be biased by a judicious choice in silane.

Short abstract

Late-stage skeletal editing of peptide −SS− bonds through bis-dehydroalanine intermediates provides ready access to chemically unique −CC− carbocycles with enhanced biopharmaceutical properties.

Introduction

Cyclic peptides are among the most popular modalities for new peptide therapeutics.1−3 Cyclization enhances the metabolic stability of linear peptides to enzymatic hydrolysis.4−8 Cyclization also enhances cell permeability by reducing overall polarity and hydrogen bonding9−13 and potency by stabilizing peptide conformations that better complement the target binding site.14−17 Many peptide therapeutics take advantage of disulfide bonds between two cysteine residues (−SS−) to form the peptide cycle. However, the susceptibility of −SS– bonds to reductive ring-opening can be a metabolic liability. Disulfide bonds are redox sensitive and are prone to rapid reductive cleavage, which shortens their half-life in vivo.18,19 Disulfide linkages can also participate in disulfide-exchange reactions with glutathione or cellular proteins having free thiol groups, resulting in protein modification and the generation of neo-antigens.20,21 Hence, modern cyclic peptide drugs aim to replace labile −SS– bonds with chemically benign −CC– linkages (as shown for atosiban, Figure 1).22 This can be accomplished using scaffold-based cyclization technologies such as ring closing metathesis (RCM)23 or palladium cross-coupling (Heck or Suzuki),24−26 wherein unique pairs of synthetic amino acids are first positioned in the peptide by solid-phase peptide synthesis (SPPS) and then coupled together to form a single carbocyclic product. Alternatively, one can start from an orthogonally protected diamino diacid linker and use amide bond forming reactions to lay in the remaining peptide around, from end-to-end, this synthetic core unit.27−30 Besides the expense and limited availability of synthetic amino acids,31 one caveat to these approaches is that the new −CC– linkage can alter the three-dimensional structure of the peptide,32 impacting its bioactivity. Identifying −CC– replacements that maximize biopharmaceutical properties (e.g., half-life) without diminishing drug potency can, therefore, require numerous carbocyclic analogs, each requiring a separate multistep SPPS to complete. A carbocyclization platform, through direct −SS– skeletal editing, could offer a highly modular way to pan out the best carbocyclic analogs for any −SS– cyclic peptide and could provide a general route to access entirely new carbocyclic frameworks from a single disulfide-containing peptide.

Figure 1.

Figure 1

Open in a new tab

Contemporary carbocyclic peptide formation and proposed “Snip-and-Stitch” strategy.

Experimental Section

We envisaged that we could cleave (i.e., “Snip”) the −SS– bond of a cyclic disulfide-containing peptide into a pair of electrophilic dehydroalanine (Dha) residues. Then, by combining the bis-Dha peptide with an appropriate bridging group (e.g., a bis-radical, bis-anion, or bis-metallic species), we could insert (i.e., “Stitch”) a library of new linker groups in place of the original −SS– bond in one convenient step. To test our proposed diversification strategy, we needed to find (1) a general method for converting the −SS– bond of a macrocyclic peptide into two Dha residues, (2) a functional precursor for inserting diverse linker chemotypes in place of the −SS– bond, and (3) chemistry to mediate bridge installation. We selected terlipressin, an −SS– containing cyclic dodecapeptide previously evaluated in the clinic to treat hepatorenal syndrome type-1,33 as a model substrate for designing our Snip-and-Stitch strategy. We found that terlipressin could be converted to the unconstrained bis-Dha peptide, Dha2-terlipressin, with the combination of methyl 2,5-dibromopentanoate34 and TCEP in good yield (>60% isolated). Other reagents for bis-Dha formation were ineffective; see the Supporting Information p S20 for complete details. Next, we sought to identify reagents and chemistries to link the two Dha fragments together through unique tethering groups. The challenge here is that the overall process of macrocyclization involves the formation of two different C–C bonds, one at each Dha residue, and a net input of up to four electrons. Thus, we explored three different chemical approaches for bridge installation, namely, photoredox catalysis (single-electron transfer chemistry), transition metal catalysis (the use of organometallic reagents as bis-anion equivalents), and electrochemistry (the generation of open-shell or bis-anionic intermediates through cathodic reduction or anode-to-cathode cycling with a redox mediator). These approaches and the intermediates they generate have been shown to transform Dha residues in peptides and proteins into α-amino acids.35−38 To evaluate each platform, we prepared seven distinct linker chemotypes (Table 1, compounds A–G), each linker consisting of a central four-carbon fragment that is capped with a unique pair of functional groups that serve as latent handles for radical or anion generation (viz., X[CH2]4X). Optimal conditions for converting each linker chemotype to the corresponding radical or anionic intermediate were selected on the basis of a comprehensive survey of the literature.39−46 Linkers were evaluated in 9:1 H2O:DMSO (for transition metals), 1:1 H2O:DMSO (for photoredox catalysis), or 1:1 H2O:MeCN (for electrochemistry) at 1 mM. A brief synopsis of our results is shown in Table 1. See the Supporting Information pp S31–S50 for all entries.

Table 1. Survey of Reaction Conditions and Synthetic Platforms for Peptide Macrocyclization.

graphic file with name oc2c00456_0004.jpg

graphic file with name oc2c00456_0005.jpg

Open in a new tab
a

See the Supporting Information pp S31–S56 for full experimental details and additional reaction conditions.

Safety Statement

No unexpected or unusually high safety hazards were encountered.

Results and Discussion

We surveyed over five-hundred unique reaction conditions: seven different linker chemotypes over three different synthetic platforms. We identified two sets of conditions for converting Dha2-terlipressin to the desired −[CH2]4– carbocyclic peptide (Table 1, compound P1): (1) 1,4-diiodobutane in the presence of zinc metal (9% conversion) and (2) the combination of Ru(bpy)3 photocatalyst, Hantzsch ester (HEH), and reagent B (7% conversion). Other organometallic or photochemical methods gave varying amounts of a dialkylated byproduct P2, failed to react, or afforded considerable amounts of unidentifiable byproducts by HRMS analyses. Electrochemical methods performed on Dha2-terlipressin or on a test Dha monomer, Ac-Dha-OMe, formed only large amounts of alanine. We attempted to independently optimize both our zinc-mediated and Ru(bpy)3 photocatalyzed protocols to improve the yield of the carbocyclic peptide. We were unable to improve the yield of our photocatalyzed reaction beyond 10% conversion. Performing our zinc-mediated protocol in a solvent of 1:1 TFE:NH4Cl (sat. aq.) and adding basic copper carbonate (CuCO3·Cu(OH)2) to the reaction improved the conversion to carbocyclic peptide to 40% as a 1:1:1:1 mixture of diastereomers.47−53 A stoichiometry of 12:12:1 of Zn:Cu:diiodide gave an optimal 55% conversion to P1 and 39% to P2 with complete consumption of Dha2-terlipressin. See the Supporting Information pp S50–S56 for complete optimization details.

One drawback of the above protocol is that it forms a mixture of the desired carbocyclic peptide and a dialkylated byproduct wherein each Dha residue reacts with a single alkyl diiodide. To improve carbocyclic product selectivity, we attempted to gain some mechanistic insight into our reaction. Combining CuCO3·Cu(OH)2, Zn0, and NH4Cl in water afforded a black insoluble material, presumably a ZnII:Cu0 couple. This material slowly turned blue upon exposure to air, characteristic of reoxidation to CuII ions. We imagined that the copper metal in our couple might be able to reduce our diiodide (E1/2red = −1.44 V vs SCE for I(CH2)2I in DMF)54 to an alkyl radical via an outer-sphere electron transfer mechanism. However, this seems unlikely given the modest reducing capacity of Cu0 (Cu0/CuI = −0.26 V vs SCE in H2O, pH 6.82)55 and would necessitate that ZnII participates as a strong Lewis acid to lower the barrier to outer-sphere electron transfer. Another possibility is that a small amount of very reducing Rieke zinc is generated in situ. While we cannot rule out these possibilities, we propose that Cu0 can oxidatively insert, albeit slowly,56 into the C–I bond of the diiodide, forming an alkyl–CuII–I intermediate.57 This process should be enthalpically feasible due to the cleavage of the weak C–I bond (∼50 kcalmol–1) and formation of a comparable Cu–I bond (∼47 kcalmol–1)58−60 in addition to a CuII–C bond, reported as ∼33 kcalmol–1 for ClCuII–C3H7.61 The CuII organometallic can disproportionate to give an alkyl radical and CuI–I.53 To probe the formation of a free alkyl radical, we combined our Zn:Cu couple with 1,4-diiodobutane (1) and TEMPO· (2) in H2O:TFE. By LC-MS analysis, we observed complete conversion of the diiodide to a mono- and di-TEMPO adduct (3 and 4, respectively), wherein one or both iodine atoms of the diiodide were replaced by TEMPO, Figure 2A. In a separate set of experiments with cyclopropylmethyl iodide (5) as a radical clock and Ac-Dha-OMe (6) as a surrogate electrophile for our bis-Dha-peptide, we obtained only the ring-opened product (7) under our reaction conditions (26% 1H NMR yield), Figure 2B. The formation of a free alkyl radical therefore seems plausible, and its generation via disproportionation of an intermediate Alkyl-CuII–I is probable. The radical intermediate then adds to a single Dha residue in our bis-Dha peptide to give a monoalkylated species, wherein one iodine atom is retained on the linker. From here, one of two possible scenarios can occur: (1) the second iodine atom is cleaved to a primary alkyl radical, which adds to the second Dha residue in our peptide, forming the carbocyclic product, or (2) another equivalent of diiodide in solution is reduced to a radical intermediate, which adds to the remaining Dha residue in our peptide, forming the dialkylated product after both iodine atoms have been reductively excised. The fact that we observe the cyclic and dialkylated products in similar proportions suggests that both pathways are likely.

Figure 2.

Figure 2

Open in a new tab

Mechanistic studies and proposed mechanism. (A–D) Mechanistic and computational studies. (E) The influence of hydrosilanes on diastereoselectivity of setmelanotide cyclization. (F) Proposed mechanism of “Snip-and-Stitch” cyclization. See the Supporting Information pp S106–S117 for full experimental details.

A reagent that could mediate ring closure might bias our reaction in favor of cyclization. An ideal reagent would homolytically cleave the remaining C–I bond on the linker and facilitate the formation of a new C–C bond at the second Dha residue in our peptide. To satiate these requirements, we investigated hydrosilanes. The α-carbonyl radical, formed after addition of an alkyl radical to a Dha residue, has a BDE of ∼87 kcalmo1–1 (calculated for Ac-Ala-NHCH3 at the B3LYP 6-311+G** level of theory). The Si–H bond for some hydrosilanes is weaker than the α-carbonyl-H bond,62 suggesting that a favorable hydrogen-atom transfer (HAT) from the hydrosilane to the α-carbonyl radical can occur, yielding an α-amino acid and a silyl radical. The silyl radical can then abstract the remaining iodine atom63 from the linker, affording a nucleophilic carbon-centered radical proximal to, and poised to react with, the second Dha residue in our peptide (Si–I BDE ∼ 80 kcalmol–1 vs C–I BDE ∼ 54 kcalmol–1).64 Experimentally, we found that hydrosilane HSiMe2Ph (8) improved product selectivity in favor of cyclization (Table 1). The overall conversion was comparable, but the formation of mono- and dialanine peptides (from Dha residues) was now observed in addition to smaller amounts of dialkylated byproduct.

To test the ability of phenyldimethylhydrosilane (H-SiMe2Ph) to quench an α-carbonyl radical through hydrogen-atom transfer and to generate an alkyl radical via iodine atom abstraction, we performed additional mechanistic experiments. While it is well-known that silyl radicals can abstract halogen atoms,46,65−67 the ability of a hydrosilane to transfer a hydrogen atom to an α-carbonyl radical in an amino acid has not been observed previously. We used Ac-Dha-OMe acceptor and cyclopropylmethyl iodide to separately investigate each process. To assess hydrogen atom transfer (HAT), we combined our Dha acceptor and cyclopropylmethyl iodide with our Zn:Cu couple and a nonexchangeable (with protonaceous solvent) deutero-silane D-SiMe2Ph (10), Figure 2C. We observed the ring opened amino acid product with an α-deuterium atom in 31% yield (48% d-content), compound 11. When the reaction was performed with the hydrosilane congener H-SiMe2Ph in D2O:TFE, a 45% yield (65% d-content) of the ring opened product with an α-deuterium atom was obtained. This suggests that HAT from H-SiMe2Ph to Dha is viable but is not the only source of hydrogen in our reaction. To assess iodine abstraction, we removed Zn:Cu from the reaction and instead used one of a myriad of reagents to convert H-SiMe2Ph to halidophilic ·SiMe2Ph. Unfortunately, the thermal and photolytic instability of our iodide, admixed with competitive halogen abstraction, complicated our studies, and we were not able to observe the ring opened amino acid product or I-SiMe2Ph (Supporting Information pp S110–S112). However, computations suggest that the generation of ·SiMe2Ph (13) by HAT to an α-carbonyl radical (12) followed by iodine atom abstraction to give I–SiMe2Ph should be a favorable process overall (−11 kcalmol–1, Figure 2D). One explanation for the competitive formation of the dialkylated product in our peptide cyclization reaction could be that electron transfer from our Zn:Cu couple (to form an α-carbanion at Dha) outcompetes HAT from the hydrosilane in some instances. This is supported by our experimental observation that D2O is able to incorporate deuterium atoms into our ring-opened amino acid product.

We prepared and tested a second bis-Dha peptide, Dha2-setmelanotide. Setmelanotide (SMT) is a cyclic −SS– containing octapeptide that was approved by the FDA in 2020 to treat genetic-associated obesity.68 Under our optimized cyclization conditions with 1,5-diiodopentane, SMT produced all four possible cyclic peptide diastereomers in an ∼14:6:3:1 ratio with two diastereomers being heavily favored. All four diastereomers were produced in equal amounts when H-SiMe2Ph was removed from the reaction (Figure 2E). This unexpected result led us to investigate the effect of other hydrosilanes in our reaction (see the Supporting Information p S54 and pp S112–S118 for all experimental data). For SMT, we found that hydrosilanes (30 equiv) having Si–H BDE ≥ 96 kcalmol–1 (determined computationally at the B3LYP 6-311+G** level of theory) were best at biasing cyclization. Hydrosilanes with BDEs < 96 kcalmol–1 gave more dialkylated product. Although many of the hydrosilanes we examined could enforce cyclization, they did not affect diastereoselectivity. Interestingly, tri-n-butylhydrosilane (9; H–Si(nBu)3) afforded only three of the four cyclic SMT diastereomers in an ∼1:0:10:6 ratio, favoring two diastereomers that were not produced in significant quantities when H-SiMe2Ph was used as additive. Between H-SiMe2Ph and n-tributylhydrosilane, we can bias cyclization in favor of two different sets of the four possible cyclic peptide diastereomers of SMT (Figure 2E). The capacity of achiral hydrosilanes to bias the stereochemistry of amino acids formed by radical addition to a prochiral dehydroalanine residue has not been reported previously, and this has untapped potential for synthetic peptide chemistry. This also lends further support to the important role of hydrosilane in our proposed cyclization mechanism, as depicted in Figure 2F. Because of its unique ability to bias our cyclization reaction and its cleaner reaction profile, we proceeded in our studies with H-SiMe2Ph as additive.

To obtain sufficient quantitates of our SMT carbocyclic peptide, we performed our diversification protocol on a scale of 5 or 10 mg of Dha2-setmelanotide. The efficiency of our reaction was not affected on either scale when 1,5-diiodopentane was used as linker. We explored three different methods to isolate the carbocyclic product formed in our scaled reaction. We elected not to use high-performance liquid chromatography, a sufficient but rather slow purification strategy, in lieu of exploring alternative strategies that would be faster and more available to most synthetic and medicinal chemists. We examined (1) liquid-phase extraction using an aqueous solution of saturated ammonium sulfate and various organic solvents,69 (2) solid-phase extraction (SPE) using a Waters Oasis HLB cartridge,70 and (3) liquid-phase flash chromatography. Of these, flash chromatography afforded the cyclic product (and its individual diastereomers) in high purity (>90%), using an eluent of H2O/0.1%TFA:EtOH/0.1%TFA. This strategy is particularly useful when purifying large quantities of carbocyclic peptides that would be unsuitable for HPLC. (The cyclic products could not be separated using H2O:MeCN or H2O:MeOH as eluents.) For these reasons, we used C18 flash chromatography to purify our cyclic peptides.

We assessed other diiodide linkers for bis-Dha peptide cyclization using Dha2-setmelanotide. Primary alkyl diiodides (I(CH2)nI, n = 4–8 carbons; Table 2 compounds 14–18) were first evaluated as −SS– replacements. These substrates worked well in our diversification platform, furnishing C4–8-SMT carbocyclic analogs in 24–38% conversion. Diiodomethane (19) afforded the methylene bridged (ring-contracted) carbocycle in 22% conversion and several intractable byproducts. 1,2-Diiodoethane (20), prone to ethylene gas formation, did not furnish the desired macrocycle. Only unreacted Dha2-setmelanotide was recovered. Diiodides containing an ethylene glycol spacer (PEG-SMT; 21), a perfluoroalkyl unit (F12-SMT; 22), and an adamantane polycycle (23) afforded the desired macrocyclic products in good overall conversions (28–47%). Finally, cyclohexyl diiodide (24), benzylic diiodide (25), and phenyl diiodide (Ph-SMT; 26) furnished new macrocyclic products in useful conversions (17–35%), Table 2. It is important to point out that our products were all isolated (0.09–2.91 mg) as a mixture of diastereomers in an average amount of 0.61 mg at >90% purity. However, individual peptide diastereomers can be separated by our flash chromatography procedure when desirable. Our lab has shown that mixtures of peptide diastereomers isolated in greater than 0.05 mg and exceeding 65% purity are more than sufficient for completing accurate biochemical experiments.70 The data obtained from these assays compares well with experiments performed using single diastereomer products. As a word of caution, using mixtures of peptide diastereomers is very useful when surveying large numbers of peptides for relative biochemical activity. Optimal substitutions generally lead to order of magnitude enhancements.71−73 However, separating the mixture and testing individual diastereomers is necessary to ascribe physiochemical properties to a specific peptide sequence. This becomes rather important when dealing with certain peptides whose molecular mechanism, i.e., ability to self-assemble74 or penetrate cell membranes,75 depends on its innate chirality.

Table 2. Scope of Diiodides for Setmelanotide Cyclization and Survey of Bioactive Peptides for “Snip-and-Stitch” Cyclization.

graphic file with name oc2c00456_0006.jpg

graphic file with name oc2c00456_0007.jpg

Open in a new tab
a

All reactions were performed using 951 nmol of Dha2-setmelanotide, 5 equiv. of diiodide, 30 equiv. of CuCO3·Cu(OH)2, 60 equiv. of zinc mesh, and 10 equiv. of HSiMe2Ph in a solution of 1:1:2 sat. aq. NH4Cl:H2O:TFE (1 mM) for 16 h. Yields are reported as % conversion to cyclic products at 280 nm.

b

Reaction performed using 10 equiv. of diiodide.

c

All reactions were performed using 5.0 mg of Dha2-peptide, 5 equiv. of diiodide, 30 equiv. of CuCO3·Cu(OH)2, 60 equiv. of zinc mesh, and 10 equiv. of HSiMe2Ph in a solution of 1:1:2 sat. aq. NH4Cl:H2O:TFE (1 mM) for 16 h. Yields are reported as % conversion to cyclic products at 214 nm.

We examined other bioactive peptides, including several FDA approved peptide drugs for −SS– bond diversification. We assessed eptifibatide (platelet inhibitor),76 desmopressin (antidiuretic),77 and vapreotide (vasoconstrictor).78 For these studies, we used 1,5-diiodopentane as a standard linker. We found that bis-Dha analogs of each peptide could be formed and reacted under our diversification conditions to afford new carbocyclic peptides in conversions of 22–44%, Table 2 compounds 27–29. The new cyclic products were readily isolated by flash chromatography, as shown for eptifibatide in Table 2. For eptifibatide and desmopressin, the C-terminal thiol is converted to an acrylamide rather than a prochiral Dha residue. Hence, only two cyclic peptide diastereomers are generated in these cases. While our results show that our cyclization method can fashion head-to-tail (eptifibatide), side chain-to-side chain (vapreotide and terlipressin), and head-to-side chain (desmopressin) peptide cycles, they also provide us with additional insights into our cyclization mechanism. First, whereas the two diastereomers of the dialkylated product of eptifibatide are formed in an ∼1:1 ratio, the two diastereomers of the cyclic peptide are formed in ∼2:1 (see Table 2). This highly suggests that ring closure from one diastereomer is more favored over the other diastereomer, encouraging a single diastereomer product to form. Thus, in some cases, our cyclization method can favor a single diastereomer product. Second, while desmopressin and terlipressin have nearly identical sequences, including the positioning of their Dha residues, desmopressin cyclizes >10-fold more efficiently with almost no dialkylated byproduct being observed. Thus, intrinsic geometries may be more important for cyclization than any specific sequence or Dha loci.

We next examined the effect of our linkers on the biopharmaceutical properties of setmelanotide. The capacity of setmelanotide (SMT) to regulate appetite depends on its ability to penetrate the blood–brain barrier and to activate melanocortin-4 (MC4) receptors in the brain.79,80 Replacing the −SS– bond of SMT with more lipophilic −CC– linkages could improve the CNS permeability of SMT and could also enhance its proteolytic stability. Hence, we determined the aqueous solubility, cellular permeability (log Peh), and general stability for some of our new carbocyclic analogs, namely, C4-SMT, PEG-SMT, F12-SMT, and Ph-SMT, and compared them to SMT. For aqueous solubility, we measured solvation in deionized water (pH 6 at 25 °C). We found that our carbocyclic peptides were completely soluble at a concentration of 1 mg of peptide per 1 mL of water. To assess cell permeability, we measured the partition coefficient Peh of our carbocyclic peptides in a mixture of ethylene glycol and heptane.81−84 Previous studies by Borchardt and co-workers showed that the permeabilities (log Peh) of peptides obtained using this partitioning system agreed well with permeabilities measured from an in vitro model of the blood–brain barrier and from physiologic saline to rat brain.82 Thus, log Peh values are a good approximation of in vivo permeabilities. For reference, log Peh of water immiscible (brain penetrable) toluene = 0.994, and log Peh of water miscible (brain impenetrable) benzamide = −3.69. Common small molecule CNS drugs have log Peh values between −1.5 and −2.5. Examples include zolantidine (log Peh −1.47), clonidine (log Peh −1.80), and antipyrine (log Peh −2.28).78 For SMT, we determined log Peh = −1.16, reflective of its good water solubility and mild blood–brain permeability. For our carbocyclic peptides C4-SMT, Ph-SMT, F12-SMT, and PEG-SMT, we measured log Peh values of −1.52, −0.57, −0.47, and −0.45, respectively (Figure 3). Thus, many of our carbocyclic analogs should have improved (up to 2.6-fold) blood–brain penetrance in vivo. Finally, we determined the stability of our carbocyclic peptides to aqueous hydrolysis and to reductive cleavage by glutathione (GSH), an approximate measure of their plasma stability.85 GSH in the cytoplasm can reduce disulfide bonds to dicysteine peptides and can also cleave disulfide bonds through a disulfide exchange reaction.18−21 Hydrolysis of disulfide bonds has also been observed, and this can result in the loss of one or both sulfur atoms from the peptide and in several cleavage byproducts.86−89 All measurements were compared to setmelanotide (SMT). As expected, SMT underwent disulfide exchange (2% mixed disulfide after 24 h) in the presence of 1 equiv. of GSH at physiological conditions (pH 7.4, 37 °C). Increasing the amount of GSH to 10 equiv. afforded more of the mixed disulfide (17%). No disulfide exchange was observed in the case of our carbocyclic analogs, which lack a disulfide bond. To assess hydrolytic stability, we dissolved SMT in pH 8.5 water and incubated the solution at 50 °C for 16 h. The products were analyzed by LC-MS. We observed the loss of a single sulfur atom (−32 m/z) from SMT. Only 5% SMT remained intact. In comparison, our carbocyclic peptides were susceptible to racemization at pH 8.5, but the peptide cycles remained completely intact. The only “odd” result came in the case of F12-SMT, which underwent extensive protodefluorination, with up to four fluorine atoms being lost. No C-terminal deamidation was observed for any peptide. Our carbocyclic analogs are, therefore, less likely to lose their biological activity due to processes that cleave the peptide cycle. Taken together, our carbocyclic analogs display superior cellular permeability and general stability and also maintain good aqueous solubility, thus imparting them with pharmacokinetic properties unrivalled by ordinary −SS– cyclic peptides.

Figure 3.

Figure 3

Open in a new tab

Permeability values (log Peh) for setmelanotide analogs. For setmelanotide, log Peh = −1.16.

Conclusions

In conclusion, we have developed a first-generation Snip-and-Stitch platform to routinely transform disulfide bonds into new C–C bonds. We demonstrate the ability of our newly minted platform to produce entirely new classes of peptide carbocycles with improved biopharmaceutical properties. Our mechanistic studies detail the multifarious role of a hydrosilane in guiding peptide cyclization and for achieving stereospecific outcomes.

Acknowledgments

This work was performed in the Department of Medicinal Chemistry at the University of Kansas and supported by the School of Pharmacy, University of Kansas, and the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under award numbers P20GM113117 and R35GM147169. This work was supported by the National Institutes of Health Graduate Training at the Biology Chemistry Interface Grant T32 GM132061 from the National Institutes of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank Jacob R. Immel, Maheshwerreddy Chilamari, and Alonso Rodriguez Ugalde for their help in reviewing this manuscript. We also thank Dr. Justin Douglas for assistance with the collection of 1D and 2D NMR spectra of select peptides.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acscentsci.2c00456.

  • Additional information regarding peptide and small molecule syntheses, reaction optimizations, experimental procedures and purifications, product characterization, and computational and spectral data (PDF)

The authors declare no competing financial interest.

The version of this paper that was published ASAP October 28, 2022, contained errors in the TOC/abstract graphic and Figure 1. The corrected version was reposted October 28, 2022.

Supplementary Material

oc2c00456_si_001.pdf (14.1MB, pdf)

References

  1. Joo S. H. Cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther. (Seoul) 2012, 20, 19–26. 10.4062/biomolther.2012.20.1.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Choi J.-S.; Joo S. H. Recent Trends in Cyclic Peptides as Therapeutic Agents and Biochemical Tools. Biomol. Ther. (Seoul) 2020, 28, 18–24. 10.4062/biomolther.2019.082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Vinogradov A. A.; Yin Y.; Suga H. Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. J. Am. Chem. Soc. 2019, 141, 4167–4181. 10.1021/jacs.8b13178. [DOI] [PubMed] [Google Scholar]
  4. Li X.; Wang S.; Zhu X.; Zhangsun D.; Wu Y.; Luo S. Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB. Marine Drugs 2020, 18, 180. 10.3390/md18040180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clark R. J.; Fischer H.; Dempster L.; Daly N. L.; Rosengren K. J.; Nevin S. T.; Meunier F. A.; Adams D. J.; Craik D. J. Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the α-conotoxin MII. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 13767–13772. 10.1073/pnas.0504613102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ngo K. H.; Yang R.; Das P.; Nguyen G. K. T.; Lim K. W.; Tam J. P.; Wu B.; Phan A. T. Cyclization of a G4-specific peptide enhances its stability and G-quadruplex binding affinity. Chem. Commun. 2020, 56, 1082–1084. 10.1039/C9CC06748E. [DOI] [PubMed] [Google Scholar]
  7. Chan L. Y.; Zhang V. M.; Huang Y.-h.; Waters N. C.; Bansal P. S.; Craik D. J.; Daly N. L. Cyclization of the Antimicrobial Peptide Gomesin with Native Chemical Ligation: Influences on Stability and Bioactivity. ChemBioChem. 2013, 14, 617–624. 10.1002/cbic.201300034. [DOI] [PubMed] [Google Scholar]
  8. Rozek A.; Powers J.-P. S.; Friedrich C. L.; Hancock R. E. W. Structure-Based Design of an Indolicidin Peptide Analogue with Increased Protease Stability. Biochemistry 2003, 42, 14130–14138. 10.1021/bi035643g. [DOI] [PubMed] [Google Scholar]
  9. Dougherty P. G.; Sahni A.; Pei D. Understanding Cell Penetration of Cyclic Peptides. Chem. Rev. 2019, 119, 10241–10287. 10.1021/acs.chemrev.9b00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Matsson P.; Doak B. C.; Over B.; Kihlberg J. Cell permeability beyond the rule of 5. Adv. Drug Delivery Rev. 2016, 101, 42–61. 10.1016/j.addr.2016.03.013. [DOI] [PubMed] [Google Scholar]
  11. Beck J. G.; Chatterjee J.; Laufer B.; Kiran M. U.; Frank A. O.; Neubauer S.; Ovadia O.; Greenberg S.; Gilon C.; Hoffman A.; Kessler H. Intestinal Permeability of Cyclic Peptides: Common Key Backbone Motifs Identified. J. Am. Chem. Soc. 2012, 134, 12125–12133. 10.1021/ja303200d. [DOI] [PubMed] [Google Scholar]
  12. Thansandote P.; Harris R. M.; Dexter H. L.; Simpson G. L.; Pal S.; Upton R. J.; Valko K. Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties. Bioorg. Med. Chem. 2015, 23, 322–327. 10.1016/j.bmc.2014.11.034. [DOI] [PubMed] [Google Scholar]
  13. Ernenwein D.; St. John S. E.; Stewart A. J.; Morimoto B. H.; Chmielewski J.; Lipton M. A. Structural studies and cyclization of the neuroprotective octapeptide NAPVSIPQ to improve cell permeability. Peptide Sci. 2020, 112, e24179 10.1002/pep2.24179. [DOI] [Google Scholar]
  14. Xu S.; Li H.; Shao X.; Fan C.; Ericksen B.; Liu J.; Chi C.; Wang C. Critical Effect of Peptide Cyclization on the Potency of Peptide Inhibitors against Dengue Virus NS2B-NS3 Protease. J. Med. Chem. 2012, 55, 6881–6887. 10.1021/jm300655h. [DOI] [PubMed] [Google Scholar]
  15. Tørfoss V.; Isaksson J.; Ausbacher D.; Brandsdal B.-O.; Flaten G. E.; Anderssen T.; Cavalcanti-Jacobsen C. d. A.; Havelkova M.; Nguyen L. T.; Vogel H. J.; Strøm M. B. Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β2,2-amino acid. J. Pept. Sci. 2012, 18, 609–619. 10.1002/psc.2441. [DOI] [PubMed] [Google Scholar]
  16. Yousif A. M.; Minopoli M.; Bifulco K.; Ingangi V.; Di Carluccio G.; Merlino F.; Motti M. L.; Grieco P.; Carriero M. V. Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes. PLoS One 2015, 10, e0126172 10.1371/journal.pone.0126172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Oudhoff M. J.; Kroeze K. L.; Nazmi K.; van den Keijbus P. A. M.; van’t Hof W.; Fernandez-Borja M.; Hordijk P. L.; Gibbs S.; Bolscher J. G. M.; Veerman E. C. I. Structure-activity analysis of histatin, a potent wound healing peptide from human saliva: cyclization of histatin potentiates molar activity 1000-fold. FASEB J. 2009, 23, 3928–3935. 10.1096/fj.09-137588. [DOI] [PubMed] [Google Scholar]
  18. Góngora-Benítez M.; Tulla-Puche J.; Albericio F. Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics. Chem. Rev. 2014, 114, 901–926. 10.1021/cr400031z. [DOI] [PubMed] [Google Scholar]
  19. Cumming R. C.; Andon N. L.; Haynes P. A.; Park M.; Fischer W. H.; Schubert D. Protein Disulfide Bond Formation in the Cytoplasm during Oxidative Stress. J. Biol. Chem. 2004, 279, 21749–21758. 10.1074/jbc.M312267200. [DOI] [PubMed] [Google Scholar]
  20. Chandrasekhar S.; Epling D. E.; Sophocleous A. M.; Topp E. M. Thiol-Disulfide Exchange in Peptides Derived from Human Growth Hormone. J. Pharm. Sci. 2014, 103, 1032–1042. 10.1002/jps.23906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rabenstein D. L.; Yeo P. L. Thiol/Disulfide Exchange Reactions of Captopril and Penicillamine with Arginine Vasopressin and Oxytocin. Bioorg. Chem. 1995, 23, 109–118. 10.1006/bioo.1995.1009. [DOI] [Google Scholar]
  22. Stymiest J. L.; Mitchell B. F.; Wong S.; Vederas J. C. Synthesis of Oxytocin Analogues with Replacement of Sulfur by Carbon Gives Potent Antagonists with Increased Stability. J. Org. Chem. 2005, 70, 7799–7809. 10.1021/jo050539l. [DOI] [PubMed] [Google Scholar]
  23. Gleeson E. C.; Jackson W. R.; Robinson A. J. Ring-closing metathesis in peptides. Tetrahedron Lett. 2016, 57, 4325–4333. 10.1016/j.tetlet.2016.08.032. [DOI] [Google Scholar]
  24. Elder A. M.; Rich D. H. Two Syntheses of the 16- and 17-Membered DEF Ring Systems of Chloropeptin and Complestatin. Org. Lett. 1999, 1, 1443–1446. 10.1021/ol990990x. [DOI] [PubMed] [Google Scholar]
  25. Afonso A.; Feliu L.; Planas M. Solid-phase synthesis of biaryl cyclic peptides by borylation and microwave-assisted intramolecular Suzuki-Miyaura reaction. Tetrahedron 2011, 67, 2238–2245. 10.1016/j.tet.2011.01.084. [DOI] [Google Scholar]
  26. Byk G.; Cohen-Ohana M.; Raichman D. Fast and versatile microwave-assisted intramolecular Heck reaction in peptide macrocyclization using microwave energy. Peptide Sci. 2006, 84, 274–282. 10.1002/bip.20411. [DOI] [PubMed] [Google Scholar]
  27. Cui H.-K.; Guo Y.; He Y.; Wang F.-L.; Chang H.-N.; Wang Y.-J.; Wu F.-M.; Tian C.-L.; Liu L. Diaminodiacid-Based Solid-Phase Synthesis of Peptide Disulfide Bond Mimics. Angew. Chem., Int. Ed. 2013, 52, 9558–9562. 10.1002/anie.201302197. [DOI] [PubMed] [Google Scholar]
  28. Gleeson E. C.; Wang Z. J.; Robinson S. D.; Chhabra S.; MacRaild C. A.; Jackson W. R.; Norton R. S.; Robinson A. J. Stereoselective synthesis and structural elucidation of dicarba peptides. Chem. Commun. 2016, 52, 4446–4449. 10.1039/C5CC10540D. [DOI] [PubMed] [Google Scholar]
  29. Qi Y.-K.; Qu Q.; Bierer D.; Liu L. A Diaminodiacid (DADA) Strategy for the Development of Disulfide Surrogate Peptides. Chem.—Asian J. 2020, 15, 2793–2802. 10.1002/asia.202000609. [DOI] [PubMed] [Google Scholar]
  30. Pascoe C. A.; Engelhardt D. B.; Rosana A. R. R.; van Belkum M. J.; Vederas J. C. Methylene Analogues of Neopetrosiamide as Potential Antimetastatic Agents: Solid-Supported Synthesis Using Diamo Diacids for Pre-Stapling of Peptides with. Multiple Disulfides. Org. Lett. 2021, 23, 9216–9220. 10.1021/acs.orglett.1c03532. [DOI] [PubMed] [Google Scholar]
  31. Schwieter K. E.; Johnston J. N. On-Demand Complex Peptide Synthesis: An Aspirational (and Elusive?) Goal for Peptide Synthesis. J. Am. Chem. Soc. 2016, 138, 14160–14169. 10.1021/jacs.6b08663. [DOI] [PubMed] [Google Scholar]
  32. Jwad R.; Weissberger D.; Hunter L. Strategies for Fine-Tuning the Conformations of Cyclic Peptides. Chem. Rev. 2020, 120, 9743–9789. 10.1021/acs.chemrev.0c00013. [DOI] [PubMed] [Google Scholar]
  33. Wong F.; Pappas S. C.; Curry M. P.; Reddy K. R.; Rubin R. A.; Porayko M. K.; Gonzalez S. A.; Mumtaz K.; Lim N.; Simonetto D. A.; Sharma P.; Sanyal A. J.; Mayo M. J.; Frederick R. T.; Escalante S.; Jamil K. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N. Eng. J. Med. 2021, 384, 818–828. 10.1056/NEJMoa2008290. [DOI] [PubMed] [Google Scholar]
  34. Morrison P. M.; Foley P. J.; Warriner S. L.; Webb M. E. Chemical generation and modification of peptides containing multiple dehydroalanines. Chem. Commun. 2015, 51, 13470–13473. 10.1039/C5CC05469A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Peng X.; Xu K.; Zhang Q.; Liu L.; Tan J. Dehydroalanine modification sees the light: a photochemical conjugate addition strategy. Trends Chem. 2022, 4, 643–657. 10.1016/j.trechm.2022.04.008. [DOI] [Google Scholar]
  36. Bogart J. W.; Bowers A. A. Dehydroamino acids: chemical multi-tools for late-stage diversification. Org. Biomol. Chem. 2019, 17, 3653–3669. 10.1039/C8OB03155J. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Larionov V. A.; Stoletova N. V.; Maleev V. I. Advances in Asymmetric Amino Acid Synthesis Enabled by Radical Chemistry. Adv. Synth. Catal. 2020, 362, 4325–4367. 10.1002/adsc.202000753. [DOI] [Google Scholar]
  38. Zhang M.; He P.; Li Y. Contemporary Approaches to α,β-Dehydroamino Acid Chemical Modifications. Chem. Res. Chin. Univ. 2021, 37, 1044–1054. 10.1007/s40242-021-1307-z. [DOI] [Google Scholar]
  39. Chilamari M.; Immel J. R.; Bloom S. General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media. ACS Catal. 2020, 10, 12727–12737. 10.1021/acscatal.0c03422. [DOI] [Google Scholar]
  40. Chu L.; Ohta C.; Zuo Z.; MacMillan D. W. C. Carboxylic Acids as A Traceless Activation Group for Conjugate Additions: A Three-Step Synthesis of (±)-Pregabalin. J. Am. Chem. Soc. 2014, 136, 10886–10889. 10.1021/ja505964r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nawrat C. C.; Jamison C. R.; Slutskyy Y.; MacMillan D. W. C.; Overman L. E. Oxalates as Activating Groups for Alcohols in Visible Light Photoredox Catalysis: Formation of Quaternary Centers by Redox-Neutral Fragment Coupling. J. Am. Chem. Soc. 2015, 137, 11270–11273. 10.1021/jacs.5b07678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Okada K.; Okamoto K.; Morita N.; Okubo K.; Oda M. Photosensitized decarboxylative Michael addition through N-(acyloxy)phthalimides via an electron-transfer mechanism. J. Am. Chem. Soc. 1991, 113, 9401–9402. 10.1021/ja00024a074. [DOI] [Google Scholar]
  43. Wang M.; Wang C.; Huo Y.; Dang X.; Xue H.; Liu L.; Chai H.; Xie X.; Li Z.; Lu D.; Xu Z. Visible-light-mediated catalyst-free synthesis of unnatural α-amino acids and peptide macrocycles. Nat. Commun. 2021, 12, 6873. 10.1038/s41467-021-27086-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wright T. H.; Bower B. J.; Chalker J. M.; Bernardes G. J. L.; Wiewiora R.; Ng W.-L.; Raj R.; Faulkner S.; Vallée M. R. J.; Phanumartwiwath A.; Coleman O. D.; Thézénas M.-L.; Khan M.; Galan S. R. G.; Lercher L.; Schombs M. W.; Gerstberger S.; Palm-Espling M. E.; Baldwin A. J.; Kessler B. M.; Claridge T. D. W.; Mohammed S.; Davis B. G. Posttranslational mutagenesis: A chemical strategy for exploring protein side-chain diversity. Science 2016, 354, 597–623. 10.1126/science.aag1465. [DOI] [PubMed] [Google Scholar]
  45. Yang A.; Ha S.; Ahn J.; Kim R.; Kim S.; Lee Y.; Kim J.; Söll D.; Lee H.-Y.; Park H.-S. A chemical biology route to site-specific authentic protein modifications. Science 2016, 354, 623–626. 10.1126/science.aah4428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Zhang P.; Le C. C.; MacMillan D. W. C. Silyl Radical Activation of Alkyl Halides in Metallaphotoredox Catalysis: A Unique Pathway for Cross-Electrophile Coupling. J. Am. Chem. Soc. 2016, 138, 8084–8087. 10.1021/jacs.6b04818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Shin J.-A.; Kim J.; Lee H.; Ha S.; Lee H.-Y. Cu(OTf)2-Promoted 1,4-Addition of Alkyl Bromides to Dehydroalanine. J. Org. Chem. 2019, 84, 4558–4565. 10.1021/acs.joc.9b00369. [DOI] [PubMed] [Google Scholar]
  48. Luche J. L.; Allavena C. Ultrasound in organic synthesis 16. Optimisation of the conjugate additions to α,β-unsaturated carbonyl compounds in aqueous media. Tetrahedron Lett. 1988, 29, 5369–5372. 10.1016/S0040-4039(00)82870-1. [DOI] [Google Scholar]
  49. Petrier C.; Dupuy C.; Luche J. L. Conjugate additions to α,β-unsaturated carbonyl compounds in aqueous media. Tetrahedron Lett. 1986, 27, 3149–3152. 10.1016/S0040-4039(00)84739-5. [DOI] [Google Scholar]
  50. Huang T.; Keh C. C. K.; Li C.-J. Synthesis of α-amino acid derivatives and amines via activation of simple alkyl halides by zinc in water. Chem. Commun. 2002, 2440–2441. 10.1039/B204585K. [DOI] [PubMed] [Google Scholar]
  51. Lipshutz B. H.; Huang S.; Leong W. W. Y.; Zhong G.; Isley N. A. C-C bond formation via copper-catalyzed conjugate addition reactions to enones in water at room temperature. J. Am. Chem. Soc. 2012, 134, 19985–19988. 10.1021/ja309409e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Blanchard P.; El Kortbi M. S.; Fourrey J.-L.; Robert-Gero M. A conjugate addition of primary alkyl iodide derived species to electron deficient olefins. Tetrahedron Lett. 1992, 33, 3319–3322. 10.1016/S0040-4039(00)92077-X. [DOI] [Google Scholar]
  53. Fleming F. F.; Gudipati S.; Aitken J. A. Alkenenitriles: Conjugate Additions of Alkyl Iodides with a Silica-Supported Zinc-Copper Matrix in Water. J. Org. Chem. 2007, 72, 6961–6969. 10.1021/jo0711539. [DOI] [PubMed] [Google Scholar]
  54. Ye D.; Zhang Y.; Gao X. Electrocatalytic reduction of 1,2-diiodoethane by anions of supramolecular complex of (β-CD)2/C60 in DMF solution. Electrochim. Acta 2007, 52, 6686–6691. 10.1016/j.electacta.2007.04.091. [DOI] [Google Scholar]
  55. Zhang Z.; Wang P. Highly stable copper oxide composite as an effective photocathode for water splitting via a facile electrochemical synthesis strategy. J. Mater. Chem. 2012, 22, 2456–2464. 10.1039/C1JM14478B. [DOI] [Google Scholar]
  56. Kornfilt D. J. P.; MacMillan D. W. C. Copper-Catalyzed Trifluoromethylation of Alkyl Bromides. J. Am. Chem. Soc. 2019, 141, 6853–6858. 10.1021/jacs.9b03024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Jenks C. J.; Bent B. E.; Bernstein N.; Zaera F. The Chemistry of Alkyl Iodides on Copper Surfaces. 1. Adsorption Geometry. J. Phys. Chem. B 2000, 104, 3008–3016. 10.1021/jp993021s. [DOI] [Google Scholar]
  58. Cottrell T. L.The Strengths of Chemical Bonds, 2nd ed.; Butterworth: London, 1958. [Google Scholar]
  59. Darwent B. D.National Standard Reference Data Series; National Bureau of Standards: Washington, D.C., 1970; Vol. 31. [Google Scholar]
  60. Kerr J. A. Bond Dissociation Energies by Kinetic Methods. Chem. Rev. 1966, 66, 465–500. 10.1021/cr60243a001. [DOI] [Google Scholar]
  61. Golubeva E. N.; Zhidomirov G. M.; Kokorin A. I. On the stability of copper(II) organic compounds with the σ bond Cu-C: A quantum-chemical study. Dokl. Chem. 2009, 426, 143–145. 10.1134/S0012500809060081. [DOI] [Google Scholar]
  62. Chatgilialoglu C.; Ferreri C.; Landais Y.; Timokhin V. I. Thirty Years of (TMS)3SiH: A Milestone in Radical-Based Synthetic Chemistry. Chem. Rev. 2018, 118, 6516–6572. 10.1021/acs.chemrev.8b00109. [DOI] [PubMed] [Google Scholar]
  63. Li J.-S.; Wu J. Recent Developments in the Photo-Mediated Generation of Silyl Radicals and Their Application in Organic Synthesis. ChemPhotoChem. 2018, 2, 839–846. 10.1002/cptc.201800110. [DOI] [Google Scholar]
  64. Walsh R. Bond dissociation energy values in silicon-containing compounds and some of their implications. Acc. Chem. Res. 1981, 14, 246–252. 10.1021/ar00068a004. [DOI] [Google Scholar]
  65. Sakai H. A.; Liu W.; Le C. C.; MacMillan D. W. C. Cross-Electrophile Coupling of Unactivated Alkyl Chlorides. J. Am. Chem. Soc. 2020, 142, 11691–11697. 10.1021/jacs.0c04812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. ElMarrouni A.; Ritts C. B.; Balsells J. Silyl-mediated photoredox-catalyzed Giese reaction: addition of non-activated alkyl bromides. Chem. Sci. 2018, 9, 6639–6646. 10.1039/C8SC02253D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Dong J.; Lyu X.; Wang Z.; Wang X.; Song H.; Liu Y.; Wang Q. Visible-light-mediated Minisci C-H alkylation of heteroarenes with unactivated alkyl halides using O2 as an oxidant. Chem. Sci. 2019, 10, 976–982. 10.1039/C8SC04892D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Heyder N. A.; Kleinau G.; Speck D.; Schmidt A.; Paisdzior S.; Szczepek M.; Bauer B.; Koch A.; Gallandi M.; Kwiatkowski D.; Bürger J.; Mielke T.; Beck-Sickinger A. G.; Hildebrand P. W.; Spahn C. M. T.; Hilger D.; Schacherl M.; Biebermann H.; Hilal T.; Kühnen P.; Kobilka B. K.; Scheerer P. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell Res. 2021, 31, 1176–1189. 10.1038/s41422-021-00569-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Wingfield P. Protein precipitation using ammonium sulfate. Curr. Protoc. Protein Sci. 1998, 13, A.3F.1–A.3F.8. 10.1002/0471140864.psa03fs13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Immel J. R.; Chilamari M.; Bloom S. Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids. Chem. Sci. 2021, 12, 10083–10091. 10.1039/D1SC02562G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Siriwardena T. N.; Gan B.-H.; Köhler T.; van Delden C.; Javor S.; Reymond J.-L. Stereorandomization as a Method to Probe Peptide Bioactivity. ACS Cent. Sci. 2021, 7, 126–134. 10.1021/acscentsci.0c01135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Udagawa H.; Yoneda T. H.; Masuda R.; Koide T. A Strategy for Discovering Heterochiral Bioactive Peptides by Using the OB2nP Library and SPOTs Method. ChemBioChem. 2019, 20, 2070–2073. 10.1002/cbic.201900237. [DOI] [PubMed] [Google Scholar]
  73. Berman J.; Green M.; Sugg E.; Anderegg R.; Millington D. S.; Norwood D. L.; McGeehan J.; Wiseman J. Rapid Optimization of Enzyme Substrates Using Defined Substrate Mixtures. J. Biol. Chem. 1992, 267, 1434–1437. 10.1016/S0021-9258(18)45963-7. [DOI] [PubMed] [Google Scholar]
  74. Zheng Y.; Mao K.; Chen S.; Zhu H. Chirality Effects in Peptide Assembly Structures. Bioeng. Biotechnol. 2021, 9, 703004. 10.3389/fbioe.2021.703004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Hosono Y.; Morimoto J.; Sando S. A comprehensive study on the effect of backbone stereochemistry of a cyclic hexapeptide on membrane permeability and microsomal stability. Org. Biomol. Chem. 2021, 19, 10326–10331. 10.1039/D1OB02090K. [DOI] [PubMed] [Google Scholar]
  76. Sabatino G.; D’Ercole A.; Pacini L.; Zini M.; Ribecai A.; Paio A.; Rovero P.; Papini A. M. An Optimized Scalable Fully Automated Solid-Phase Microwave-Assisted cGMP-Ready Process for the Preparation of Eptifibatide. Org. Process Res. Dev. 2021, 25, 552–563. 10.1021/acs.oprd.0c00490. [DOI] [Google Scholar]
  77. Drucker D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discovery 2020, 19, 277–289. 10.1038/s41573-019-0053-0. [DOI] [PubMed] [Google Scholar]
  78. Rai U.; Thrimawithana T. R.; Valery C.; Young S. A. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol. Ther. 2015, 152, 98–110. 10.1016/j.pharmthera.2015.05.007. [DOI] [PubMed] [Google Scholar]
  79. Clément K.; Biebermann H.; Farooqi I. S.; Van der Ploeg L.; Wolters B.; Poitou C.; Puder L.; Fiedorek F.; Gottesdiener K.; Kleinau G.; Heyder N.; Scheerer P.; Blume-Peytavi U.; Jahnke I.; Sharma S.; Mokrosinski J.; Wiegand S.; Müller A.; Weiß K.; Mai K.; Spranger J.; Grüters A.; Blankenstein O.; Krude H.; Kühnen P. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat. Med. 2018, 24, 551–555. 10.1038/s41591-018-0015-9. [DOI] [PubMed] [Google Scholar]
  80. Kühnen P.; Clément K.; Wiegand S.; Blankenstein O.; Gottesdiener K.; Martini L. L.; Mai K.; Blume-Peytavi U.; Grüters A.; Krude H. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N. Engl. J. Med. 2016, 375, 240–246. 10.1056/NEJMoa1512693. [DOI] [PubMed] [Google Scholar]
  81. Abraham M. H.; Martins F.; Mitchell R. C.; Salter C. J. Hydrogen bonding. 47. Characterization of the ethylene glycol-heptane partition system: Hydrogen bond acidity and basicity of peptides. J. Pharm. Sci. 1999, 88, 241–247. 10.1021/js980242l. [DOI] [PubMed] [Google Scholar]
  82. Chikhale E. G.; Ng K.-Y.; Burton P. S.; Borchardt R. T. Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood-Brain Barrier Permeability of Peptides. Pharm. Res. 1994, 11, 412–419. 10.1023/A:1018969222130. [DOI] [PubMed] [Google Scholar]
  83. Conradi R. A.; Hilgers A. R.; Ho N. F. H.; Burton P. S. The Influence of Peptide Structure on Transport Across Caco-2 Cells. Pharm. Res. 1991, 8, 1453–1460. 10.1023/A:1015825912542. [DOI] [PubMed] [Google Scholar]
  84. Paterson D. A.; Conradi R. A.; Hilgers A. R.; Vidmar T. J.; Burton P. S. A Non-aqueous Partitioning System for Predicting the Oral Absorption Potential of Peptides. Quant. Struct.-Act. Rel. 1994, 13, 4–10. 10.1002/qsar.19940130103. [DOI] [Google Scholar]
  85. Bogdanowich-Knipp S. J.; Chakrabarti S.; Siahaan T. J.; Williams T. D.; Dillman R. K. Solution stability of linear vs. cyclic RGD peptides. Pept. Res. 1999, 53, 530–541. 10.1034/j.1399-3011.1999.00052.x. [DOI] [PubMed] [Google Scholar]
  86. Galande A. K.; Trent J. O.; Spatola A. F. Understanding base-assisted desulfurization using a variety of disulfide-bridged peptides. Peptide Sci. 2003, 71, 534–551. 10.1002/bip.10532. [DOI] [PubMed] [Google Scholar]
  87. Gawron O.; Odstrchel G. Kinetic studies on the alkaline decomposition of cystine derivatives and peptides. J. Am. Chem. Soc. 1967, 89, 3263–3267. 10.1021/ja00989a029. [DOI] [PubMed] [Google Scholar]
  88. Robbins F. M.; Fioriti J. A. Alkaline Degradation of Cystine, Glutathione and Sulphur-containing Proteins. Nature 1963, 200, 577–578. 10.1038/200577a0. [DOI] [PubMed] [Google Scholar]
  89. Wang Z.; Rejtar T.; Zhou Z. S.; Karger B. L. Desulfurization of cysteine-containing peptides resulting from sample preparation for protein characterization by mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24, 267–275. 10.1002/rcm.4383. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oc2c00456_si_001.pdf (14.1MB, pdf)

Articles from ACS Central Science are provided here courtesy of American Chemical Society

RESOURCES